Angelito Yango, MD
Nephrology · Fort Worth, TXNPI 1982651998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,329, 5.1 times the $259 reported in 2019.
Across 181 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$752
- Travere Therapeutics, Inc.$536
- AstraZeneca$378
- Sanofi$278
- Vifor Pharma, Inc.$258
- Bayer$190
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,96899%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 38 | $752 |
| Travere Therapeutics, Inc. | 21 | $536 |
| AstraZeneca | 21 | $378 |
| Sanofi | 13 | $278 |
| Vifor Pharma, Inc. | 10 | $258 |
| Bayer | 10 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $184 |
| Veloxis Pharmaceuticals, Inc. | 6 | $179 |
| Mallinckrodt Hospital Products Inc. | 7 | $167 |
| Boehringer Ingelheim | 6 | $128 |
| Novartis | 4 | $98 |
| Mallinckrodt Enterprises LLC | 3 | $84 |
| Merck | 4 | $78 |
| Novo Nordisk | 3 | $69 |
| Calliditas Therapeutics US Inc. | 3 | $67 |
| Fresenius USA Marketing, Inc. | 3 | $61 |
| Eurofins Viracor, LLC | 2 | $60 |
| One Lambda, Inc. | 1 | $50 |
| Ardelyx, Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| GSK | 2 | $34 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Akebia Therapeutics Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
How this compares
$3,991 in reported general payments places this provider in the 70th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LivtencityMaribavir | 13 | $329,945 |
| EliquisApixaban | 11 | $14,098 |
| Mycophenolic AcidMycophenolate Sodium | 63 | $12,658 |
| Valganciclovir Hcl | 70 | $12,156 |
| XareltoRivaroxaban | 13 | $11,382 |
| Sirolimus | 22 | $10,474 |
| JardianceEmpagliflozin | 11 | $7,236 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 760 | $5,757 |
| Tacrolimus | 58 | $3,276 |
| Nifedipine ErNifedipine | 168 | $2,908 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,878 |
| Prednisone | 531 | $2,523 |
| Potassium Citrate ErPotassium Citrate | 18 | $2,459 |
| Bumetanide | 77 | $2,192 |
| Pantoprazole Sodium | 293 | $1,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Livtencity | $184 | $329,94513 claims |
| Johnson & JohnsonXarelto | $14 | $11,38213 claims |
| Boehringer IngelheimJardiance | $128 | $7,23611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.